Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
Chadwick J. et al, (2025), J Clin Pharmacol
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242.
Maddaloni E. et al, (2025), Diabetes Care, 48, e61 - e62
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.
Maddaloni E. et al, (2025), Diabetes Res Clin Pract, 223
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysis.
Juraschek SP. et al, (2025), BMJ, 388
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.
Loesch DP. et al, (2025), Nat Commun, 16
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
Dennis JM. et al, (2025), Lancet, 405, 701 - 714
Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Maddaloni E. et al, (2025), Diabetes Care, 48, 235 - 242
The Science of Diabetes and a Life of Trials: The 2024 Banting Medal for Scientific Achievement Award Lecture.
Holman RR., (2025), Diabetes, 74, 164 - 174
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
Adler AI. et al, (2025), Lancet, 405
Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study
Cardoso P. et al, (2025), Diabetes Obesity and Metabolism
Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.
Dakin HA. et al, (2025), Med Decis Making, 45, 45 - 59
Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.
Marx N. et al, (2024), Eur Heart J, 45, 5117 - 5126
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Lin B. et al, (2024), Lancet Diabetes Endocrinol
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Neves JS. et al, (2024), Eur J Heart Fail
Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.
Koychev I. et al, (2024), Alzheimers Res Ther, 16
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Gao N. et al, (2024), Pharmacoeconomics, 42, 1017 - 1028
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Adler AI. et al, (2024), Lancet, 404, 145 - 155